stockrowJazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −280.5%
- Free cash flow
- −60.4%
- Total debt
- +3.88%
Quarter to September 2026, against a year earlier
Follow JAZZ
Alert me
Jazz Pharmaceuticals PLC (JAZZ) Return on assets
Jazz Pharmaceuticals PLC's return on assets over the twelve months to 30 September 2026 was 1.76%, up 4.8 percentage points from fiscal 2025 (−3.01%). Over the past ten years it has ranged from −3.50% (fiscal 2021) to 9.88% (fiscal 2015); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −3.01% | (7.89) |
| FY2024 | 4.88% | 0.92 |
| FY2023 | 3.96% | 5.90 |
| FY2022 | −1.94% | 1.56 |
| FY2021 | −3.50% | (7.45) |
| FY2020 | 3.95% | (5.79) |
| FY2019 | 9.74% | 1.08 |
| FY2018 | 8.66% | (1.17) |
| FY2017 | 9.83% | 0.07 |
| FY2016 | 9.76% | (0.12) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ASND Ascendis Pharma A/S compare | 44.3% |
| EXEL Exelixis, Inc. compare | 33.2% |
| HALO Halozyme Therapeutics, Inc. compare | 17.1% |
| TECH Bio-Techne Corp compare | 7.07% |
| JAZZ Jazz Pharmaceuticals PLC | 1.76% |
| BMRN BioMarin Pharmaceutical Inc. compare | −0.20% |
| KYMR Kymera Therapeutics, Inc. compare | −24.4% |
| BBIO BridgeBio Pharma, Inc. compare | −37.5% |
| SMMT Summit Therapeutics PLC compare | −159.1% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on JAZZ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement